Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

National Institute of Environmental Health Sciences

Use this QR code to view the newest version of this document
Use this QR code to view the newest version of this document

Your Environment. Your Health.

Publication Detail

Title: Race and smoking status associated with paclitaxel drug response in patient-derived lymphoblastoid cell lines.

Authors: Akhtari, Farida S; Havener, Tammy M; Hertz, Daniel L; Ash, Jeremy; Larson, Alexandra; Carey, Lisa A; McLeod, Howard L; Motsinger-Reif, Alison A

Published In Pharmacogenet Genomics, (2021 Feb 01)

Abstract: The use of ex-vivo model systems to provide a level of forecasting for in-vivo characteristics remains an important need for cancer therapeutics. The use of lymphoblastoid cell lines (LCLs) is an attractive approach for pharmacogenomics and toxicogenomics, due to their scalability, efficiency, and cost-effectiveness. There is little data on the impact of demographic or clinical covariates on LCL response to chemotherapy. Paclitaxel sensitivity was determined in LCLs from 93 breast cancer patients from the University of North Carolina Lineberger Comprehensive Cancer Center Breast Cancer Database to test for potential associations and/or confounders in paclitaxel dose-response assays. Measures of paclitaxel cell viability were associated with patient data included treatment regimens, cancer status, demographic and environmental variables, and clinical outcomes. We used multivariate analysis of variance to identify the in-vivo variables associated with ex-vivo dose-response. In this unique dataset that includes both in-vivo and ex-vivo data from breast cancer patients, race (P = 0.0049) and smoking status (P = 0.0050) were found to be significantly associated with ex-vivo dose-response in LCLs. Racial differences in clinical dose-response have been previously described, but the smoking association has not been reported. Our results indicate that in-vivo smoking status can influence ex-vivo dose-response in LCLs, and more precise measures of covariates may allow for more precise forecasting of clinical effect. In addition, understanding the mechanism by which exposure to smoking in-vivo effects ex-vivo dose-response in LCLs may open up new avenues in the quest for better therapeutic prediction.

PubMed ID: 32941389 Exiting the NIEHS site

MeSH Terms: Breast Neoplasms/drug therapy*; Breast Neoplasms/genetics; Breast Neoplasms/pathology; Cell Line, Tumor; Cell Survival/drug effects; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm/genetics; Female; Humans; Middle Aged; Paclitaxel/adverse effects; Paclitaxel/pharmacology*; Pharmacogenetics; Racial Groups/genetics*; Smoking/adverse effects; Smoking/genetics*

Back
to Top